rrd1977 on RB: Remember, Dr. Taub didn't take the reins until mid-July. It appears he was handed an entangled and knotted set. He's figured the ropes out before, and he'll figure this one out. What happens in the trials is somewhat subjective to conditions. What happens in investor relations and shareholder communication is not. That is completely in the lap of the company, and can be easily repaired. It baffles me that they don't. This company needs to have a human face put on it and have it's story fleshed out a bit. Like I said, it's not that hard. Investors need almost constant hand-holding and bedside attention, especially in otcbb. It's the retail investor that will move this up to where the institutional investor will notice it. McCullough is an investment advisor, isn't he? He should know this. A quality, well-worded pr about the already FDA approved e2's progress on the modification trials with some fanfare about the name change and some carrot dangling about potential market share would be a nice start. Another head scratcher is EndoScan. Phase I was due to finish in August with immediate resumption of trials in Phase II. Updates please.
Market Data 
Markets 
AI
